The lawsuit, filed in the U.S. District Court for the Northern District of California (Robbins v. GRAIL, Inc., et al.), alleges the company misled shareholders regarding the efficacy of its Galleri multi-cancer early detection test. According to the complaint, executives touted the trial's design and real-world performance while allegedly concealing that the three-year study timeframe was insufficient to demonstrate a statistically significant reduction in late-stage cancers.

Disappointment hit the market on February 20, 2026, when GRAIL reported that the primary endpoint was not observed. The company cited a need for longer follow-up time to adequately compare the study arms, triggering a sharp decline in share price from $101.53 to $50.21. The class action, brought by Bleichmar Fonti & Auld LLP, asserts claims under the Securities Exchange Act of 1934 on behalf of investors who purchased common stock during the period in question.